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1. Introduction 
Glioblastoma is the most common form of primary brain tumors 1. About 10,000 new 
patients each year in the US are diagnosed with GBM. Despite its comparatively low 
incidence of about 2-3 new cases per 100,000 people per year (for comparison, the incidence 
of colon cancer in the US is approximately 1 new case per 1,800 people per year), the total 
number of deaths per year attributable to glioblastoma rivals that of other major cancers. 
This disparity reflects the lethal nature of the disease. If untreated, patients with 
glioblastoma generally die within 3 months of their diagnosis 2. Diffuse invasion into the 
surrounding normal cerebral parenchyma is a cardinal feature of glioblastoma, preventing 
surgical cure. In this context, it is not surprising that surgical resection alone does not 
significantly prolong patient survival 2. When maximal surgical resection is combined with 
radiation and the chemotherapeutic agent, temozolomide, the median survival of patients 
improved to 14.6 months 3. While this regimen achieves an approximate 10% five-year 
progression free survival 4, the majority of the afflicted patients succumb to the disease 
within a year of diagnosis. Effective therapeutic strategies are desperately needed. 
Despite the abundance of strategies and agents that have been tested over the last half-
century for the treatment of GBM, the single most efficacious modality and significant 
advance has been the use of post-resection radiation therapy. In 1966, the Montreal 
Neurology Institute published the first large case series that suggested a survival advantage 
in patients who received an average total post-resection IR dose of 5,000–6,000 cGy 5. Over 
the next decade, other case series corroborated those data, suggesting an improvement in 
patient survival with post-resection IR 6-9. Although interpretation of these case series is 
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confounded by their retrospective, non-randomized nature, and wide variations in radiation 
dose regimen, an overall trend of improved patient survival was seen.  
The efficacious nature of radiation therapy in glioblastoma was subsequently confirmed in 
three subsequent randomized control trials. BTSG 66-01, the first of the initial three clinical 
studies that randomized patients with newly-diagnosed malignant gliomas to with Whole-
Brain RadioTherapy (WBRT) with or without mithramycin 10. While mithramycin did not 
significantly impact survival, the survival of patients who received adjuvant WBRT were 
extended to about 5 months on average. BTSG 69-01 randomized patients post-surgical 
resection to best supportive care or chemotherapy (BCNU), with or without WBRT. Overall 
patient survival was improved with radiation therapy (with or without BCNU) when 
compared to supportive care alone. The median survival for the surgery only patient was 14 
weeks. The median survival for patients who underwent surgery followed by radiation 
therapy was 36 weeks (p<0.05). Similar results were seen in another randomized trial, 
BTSG72-01. 
A meta-analysis of 66-01, 69-01, and 72-01 11showed that patients who did not receive 
radiation or were treated with less than 4,500 cGy exhibited poor survival (median survival 
of 4.2 and 3.1 months, respectively). On the other hand, patients treated with 5,000, 5,500, 
and 6,000 cGy showed improved survival (median survival of 6.5, 8.4, and 9.8 months, 
respectively). Subsequent dose escalation beyond 6,000 cGy revealed increased neuro-
toxicity without significant therapeutic gain 12. These studies collectively established the 
dosimetry for modern glioblastoma therapy.  
It is important to note that, as a single agent, the efficacy of radiation therapy as a 
glioblastoma therapeutic has yet been matched by any chemotherapy 12. For this reason, 
radiation therapy remains a universal component in clinical trials with curative intent for 
treatment of newly diagnosed glioblastomas. Identification of agents that augment the 
efficacy of radiation therapy remains a promising strategy for glioblastoma therapy. In this 
context, we will review the molecular mechanism underlying cellular response to radiation. 
2. DNA repair and damage response following ionizing radiation 
While Ionizing Radiation (IR) has been shown to induce a plethora of cellular effects, it is 
widely held that its tumoricidal activity is largely related its effect on DNA 13. IR induces 
multiple types of DNA lesions, including damages to the nucleobase, sugar, and phosphate 
back bone 13. Ultimately, these lesions, if unrepaired, are converted into Double Stranded 
DNA Breaks (DSBs). DSBs are highly cytotoxic as the presence of a single DSB in a cell is 
sufficient to induce death 14-19. Our understanding of DNA damage response and DSB repair 
has expanded exponentially in the past decade. To make this vast information more 
accessible to the reader, we will organize the information into the following sections: 1) 
general mechanism of DSB repair, 2) mechanism by which DNA damage response activates 
DSB repair, and 3) effect of DNA damage on cell cycle progression.  
2.1 General mechanism of DSB repair 
DSBs are repaired by two major mechanisms: Non-Homologous End Joining (NHEJ) or 
Homologous Recombination (HR) 20, 21. The simplest way of repairing DSB is by re-ligation. 
This process is termed NHEJ since no significant DNA sequence homology at the broken 
ends is required. Instead, the NHEJ enzymatic machinery relies on limited processing of the 
DNA ends followed by annealing short stretches of complementary DNA sequences. 
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Because short stretches of complementary sequences occur at some regularity in the human 
genome, NHEJ is prone to the generation of mutations, deletions, as well as chromosomal 
rearrangements22.  
The second major DSB repair process is termed HR. HR initiates with extensive 5’ to 3’ end 
processing of the broken ends into large regions of single stranded tails. The resultant 3’ 
single stranded tail invades a homologous donor sequence. This strand invasion is mediated 
by enzyme(s) termed “recombinase” that coats the single stranded tail. Subsequent strand 
extension and Holliday junction resolution result in restoration of DNA continuity. The 
resolution is mediated by specific enzymes(s) termed “resolvase” 21. Because the process 
cannot proceed without extensive sequence homology, HR tends to be less prone to 
mutagenesis relative to NHEJ. Because of the requirement for a homologous donor 
sequence, HR occurs only in the S/G2/M phases of the cell cycle while NHEJ occurs 
throughout the cell cycle. Both HR and NHEJ contribute to the repair of RT induced DSBs, 
suggesting that these pathways may be functionally compensatory 23-25. Given the critical 
role of these two processes, it is not surprising they are subject to complex regulation.  
 In mammalian cells, both are carried out by multi-step processes facilitated by a large 
number of proteins. The mechanistic details of these processes remain an active area of 
investigation. Working models are described as follows.  
For NHEJ, upon DNA damage response activation (see below), the Ku70/Ku 80 
heterodimer is recruited to the break site. This protein complex forms a ring shaped 
structure to protect the broken DNA ends 26. Additionally, the heterodimer serves as a 
platform for binding of the critical kinase, DNA-PK 27, and the XRCC4-Ligase IV-XLF4 
complex 28to the site of damage. DNA-PK performs two important functions: 1) it 
phosphorylates the Ligase IV complex to facilitate the joining of DNA ends; and 2) in cases 
where DNA end processing is required before rejoining, DNA-PK binds to and recruits the 
Artemis endonuclease to perform this function. While other proteins also participate in 
NHEJ 21, in vitro reconstitution of NHEJ with these seven proteins (Ku70, Ku80, DNA-PK, 
XRCC4-Ligase IV-XLF4 complex, and Artemis) suggest that they are essential for this 
process.  
In comparison, the genetics of HR is more complex and far less well understood. Upon 
DNA damage response activation, it is thought that the BRCA1 and BRCA2 protein are 
recruited to the site of DNA damage. These two proteins were cloned by virtue of their 
inactivation in familial breast cancer cohorts (BReast CAncer genes 1 and 2) 29-31. Both 
proteins encode large molecular weight proteins that mediate multiple cellular processes to 
suppress tumor formation. One of these critical functions involves HR. It’s proposed that 
BRCA1 and 2 bind to aberrant DNA structures related to DSB ends 32, 33. Through BRCA2, 
the mammalian recombinase, RAD51, is recruited to the site of damage 34. RAD51 coats the 
DNA and facilitates the strand exchange reaction in homologous recombination 35-37. After 
strand invasion, resolution of the Holliday intermediate is mediated by a protein complex 
consisting of XRCC3 and RAD51C (two homologues of RAD51) 21, 38.  
The mechanism by which HR and NHEJ is activated in response to DNA damage is 
discussed below. 
2.2 DNA damage response 
The DNA Damage Response (DDR) refers to the signal transduction cascades that are 
triggered by DNA damages. These cascades coordinate DNA repair, cell cycle progression, 
and cell death mechanisms to facilitate the faithful transmission of genetic material after 
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DNA damage. The process initiates with the recognition of DNA damage by specialized 
“sensor” proteins. These sensor proteins, in turn, recruit and/or activate “transducer” 
proteins required for subsequent signaling to “effector” responses, such as cell cycle arrest, 
apoptosis, transcription, and DNA repair 39. Defects in DNA damage response have been 
associated with genomic instability, sensitivity to genotoxic agents, and cancer 
predisposition 40. 
Upon DNA damage, the strand discontinuities trigger complex changes in DNA topology 
secondary to histone acetylation and phosphorylation of chromatin proteins 41. The unveiled 
strand break is recognized by the Mre11-Rad50-Nbs1 (MRN) complex. In addition to serving 
as an exo/endonuclease to process the DSBs into single stranded DNA tails 42, the MRN 
complex also recruits the Ataxia Telangiectasia Mutated (ATM) protein kinase to the site of 
the DSB 43, 44. When recruited to DSBs, ATM – normally existing in an inactive dimeric form 
– dissociates and autophosphorylates on multiple residues that are thought to be important 
for activation of ATM’s kinase activity 45. The activated ATM phosphorylates the histone 
protein, H2AX, over a region of megabases surrounding a DSB 46, 47. The phosphorylated 
H2AX (also known as -H2AX), in turn, recruits the Mediator of DNA Checkpoint (MDC1) 
protein 48, 49. The MDC1 protein serves as a scaffold protein for docking of the E3 ubiquitin 
ligase complex, UBC13-RNF8 50, which serves to poly-ubiquitinate H2AX. Completion of 
this poly-ubiquitination reaction requires a second ubiquitin ligase, RNF168 51. RNF168 is 
recruited to the site of DNA damage through its interaction with HERC2 and RNF8 52. The 
poly-ubiquitination reaction alters local chromatin structure as well as provides docking site 
for the ubiquitin binding protein, RAP80. RAP80, in turn, recruits the 
BRCA1/BRCA2/RAD51 repair complex by direct physical interaction53. This complex 
initiates DSB repair by HR as well as arrests cell cycle progression in a process known as 
DNA damage checkpoint activation (see ensuing section).  
It is important to note that while the above damage response is described in a linear manner, 
parallel interactions occur at each step. For instance, MDC1, in addition to recruiting 
UBC13-RNF8, also interacts with ATM 48 and MRN 54 to stabilize the repair complex. The 
aggregate effect of these other complex interactions induces chromatin state changes 
surrounding the DSB and the localization of numerous proteins required for coordinating 
DNA repair and checkpoint regulation.  
Similar to HR, the NHEJ process can be initiated by the MRN complex upon DDR 
activation. The Mre11 protein in the complex can directly interact with the Ku70 subunit 55. 
Moreover, the RAD50 protein in the MRN complex encodes a high-affinity DNA binding 
domain and a second domain that facilitates homodimeric interactions that holds DNA ends 
in close proximity 56 to facilitate subsequent NHEJ.  
Since the MRN complex may initiate either HR or NHEJ, a central question in the field of 
DNA repair involves the mechanism of this regulation. Inappropriate activation of HR in 
the G1 phase of the cell cycle could lead to cell death. Similarly, activation of NHEJ during 
the S/G2 phases of the cell cycle could increase the rate of mutagenesis. One of the key 
mediators of this regulatory process involves the protein CTBP Interacting Protein (CTIP). In 
a landmark study 57, CTIP was found to interact with the MRN complex to promote its 
exo/endonuclease activity and process DSBs into single stranded DNA ends. Importantly, 
this activity is regulated by cell cycle dependent phosphorylation events mediated by 
Cyclin-Dependent Kinases (CDKs). In the S/G2 phase of the cell cycle, CTIP is 
phosphorylated. Thus, the MRN complex processes DSBs into single stranded tails required 
for the initiation of HR. On the other hand, in the G1 phase of the cell cycle, CTIP remains 
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unphosphorylated, and the MRN complex remains inactive as an exo/endo-nuclease. 
Without this processing, HR cannot be initiated. Thus, NHEJ becomes the predominant 
repair process.  
2.3 Effect of DNA damage on cell cycle progression 
In addition to the assembly of repair complexes as above described, DNA damage triggers 
signaling to proteins required for cell cycle progression, such as the CDK/cyclin complex. 
Generally speaking, DNA damage checkpoint regulation occurs at three distinct phases of 
the cell cycle: the G1-S transition, the intra-S-phase, and the G2-M transition. Most of what 
we understand of this transduction process involves protein phosphorylation cascades, 
though the importance of other types of reversible modifications, such as ubiquitination and 
sumoylation, are become increasingly apparent 58. Here, we will review an illustrative 
example of signal transduction between DNA damage sensors and cell cycle regulation. 
Upon recognition of DSB, the MRN complex recruits and activates the critical ATM kinase. 
The ATM kinase, in turn, phosphorylates the tumor suppressor p53 and another kinase 
termed Chk2 (Checkpoint Kinase 2) 59. ATM phosphorylation of Chk2 activates its kinase 
activity which, in turn, phosphorylates both p53 and MDM2. These phosphorylation events 
stabilize p53 by interrupting its association with its negative regulator, MDM2 60. Activated 
p53 then induces the transcription of its target genes, which include the critical regulator of 
the G1-S transition, p21 61. The binding of p21 to the CDK-cyclin complexes and prevents 
phosphorylation of the retinoblastoma protein (pRb). When in a hypophosphorylated state, 
pRb blocks cell proliferation by sequestering and altering the function of E2F transcription 
factors that control transcription of genes required for progression from G1 into S phase. 
Disruption of the pRb pathway – as occurs with mutant p53 or p21 – liberates E2Fs and 
allows cell proliferation, which renders cells insensitive to DNA damage-induced anti-
growth signals that normally operate to inhibit passage through G1 phase of the cell cycle 62.  
With regards to the G2-M checkpoint, ATM release inhibition of p53 additionally results in 
the transcriptional induction of 14-3-3 in addition to p21. The 14-3-3protein sequesters 
the cyclinB-cdc2 kinase complex in the cytoplasm and prevents nuclear phosphorylation 
events required for G2/M progression 63. Additionally, p21 binds to any residual cdc2 that 
enters the nucleus to prevent its activation. These and other ATM events prevent 
progression through the G2/M transition and afford time for DSB repair 64. 
3. Strategies for sensitization 
A prediction of the above presented model is that inhibition of any of the proteins required 
for DDR or DSB repair should lead to radiation sensitization. In general, this prediction has 
been confirmed 65. However, therapeutic agents that directly inhibit these critical proteins 
are still years from reaching clinical trial. Encouragingly, several FDA-approved agents have 
recently been shown to modulate DNA damage response. This property may be explored as 
therapeutic strategy.  
3.1 Molecular rationale for therapeutic window 
Before considering the strategy of radiation sensitization, one must first consider the 
molecular rationale for therapeutic window. After all, if normal and tumor cells were 
equally sensitized by the agent, then no therapeutic efficacy is gained.  
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A large body has yielded data suggesting that oncogene activation creates a tumor state that 
increases the accumulation of DNA damage 66-69. This damage, if unrepaired, can be converted 
into DSBs that eventually lead to cell death. To compensate for this increased DNA damage, 
the tumor cells require increased utilization of DNA repair processes 69. In this context, the 
administration of radiation introduces additional DNA damage that further taxes the already 
over-utilized repair process. This situation, in turn, increases the likelihood of an unrepaired 
DSB causing cell death. The same effect can be achieved by inhibition of DSB repair. The 
following sections will review FDA-approved agents with such properties. It is important to 
note that these agents induce pleiotropic effects beyond DSB repair inhibition. 
3.2 DNA damaging agents 
Conventional chemotherapy involves DNA damaging agents that are often used in 
conjunction with radiation. In this context, these FDA-approved agents often sensitize the 
tumoricidal effects of radiation. The mechanism of this sensitization is thought to be related 
to the generation of DNA damages that sequester critical DNA repair proteins. For instance, 
lesions generated by cisplatin bind to and sequester the Ku70/80 heterodimer and thereby 
compromise the efficiency of NHEJ 70. Further, most DNA damages induced by 
conventional chemotherapy are ultimately converted to DSBs 71. These DSBs will titrate 
away the repair proteins available to repair the DSBs induced by subsequent radiation. 
These types of mechanisms likely account for the increased glioblastoma patient survival 
observed in the context of concurrent radiation/ temozolomide treatment relative to 
radiation treatment alone 3, 4. 
3.3 Proteasome inhibitors 
As a result of extreme aneuploidy, copy-number variation, and transcriptional alteration 
that are present in many cancer cells, there is increased stress on the chaperone pathways 
(such as heat shock proteins) to maintain folding of over-expressed proteins. When the 
capacity of these chaperone proteins becomes saturated, the unfolded proteins require 
degradation by the proteasome complex 72. Thus, tumor cells exhibit increased dependency 
on proteasome function. Indeed, proteasome inhibition has been demonstrated to selectively 
ablate cancer cells both in vitro and in vivo 73. The proteasome inhibitor bortezomib has 
attained FDA-approval as a treatment for multiple myeloma and mantle cell lymphoma. 
Recent studies implicate proteasome function in DSB repair. The yeast Sem1 protein is a 
subunit of the 19S proteasome that is required for efficient HR 74. The human Sem1 
homologue, DSS1, physically interacts with the HR protein, BRCA2, and is required for its 
stability and function 75-77. Using the DR-GFP assay to directly assess HR efficiency, 
Murakawa et al. demonstrated that HR efficiency is significantly reduced by proteasome 
inhibition 78. As a whole, these studies suggest proteasome inhibition as a means to target 
HR in cancer therapy.  
The mechanism by which proteasome inhibition modulates HR remains an area of 
investigation. One hypothesis frequently put forth is the following. The proteins destined for 
proteasome degradation are typically modified by attachment of multiple ubiquitin moieties 
74. Processing of the tagged protein releases the tagged ubiquitin to replete the intracellular 
pool. Proteasome inhibition, thus, leads to accumulation of ubiquitinated proteins. This 
accumulation, in turn, depletes the intracellular ubiquitin pool. Since free ubiquitins are 
required to activate HR, the repair process is compromised by proteasome inhibition. 
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3.4 Epidermal Growth Factor Receptor (EGFR) inhibitors 
EGFR is frequently amplified or mutated in several cancer types, including Non-Small Cell 
Lung Cancer (NSCLC) and glioblastomas 79-81. As aberrant EGFR signaling is required to 
sustain tumor survival and proliferation in some cancers, targeted inhibition has led to 
selective tumor ablation 79. Clinical trial success has led to FDA-approval for treatment of 
NSCLC.  
Several studies have demonstrated that EGFR inhibition sensitized tumor cells to radiation 
65. Insights into the mechanism underlying this sensitization have been provided by several 
recent studies. One series of studies demonstrate that a subset of EGFR travels to the 
nucleus where it binds to and enhances DNA-PK activity to enhance NHEJ 82, 83}. Indeed, 
glioblastomas over-expressing an over-active form of EGFR (termed EGFRvIII) exhibit 
radiation resistance that can be abridged by treatment with DNA-PK inhibitors 84. Another 
series of studies reveal that EGFR inhibition leads to retention of BRCA1 in the cytoplasm, 
thereby causing defective HR 85. Finally, other downstream effectors of EGFR, including the 
Extracellular signal Regulated Kinase (ERK1/2) also modulates HR efficiency 86. It is likely 
that the radiation sensitization effect of EGFR inhibition represents a culmination of these 
individual effects.  
3.5 Other late stage clinical trial agents 
There are several other agents that are in mid- to late- clinical trial testing that have also 
been shown to inhibit DNA damage response. For instance, Histone DeACetylase (HDAC) 
inhibitors have been shown to down regulate the transcript level of BRCA1 87. These agents 
have also been shown to disrupt the chromatin re-organization required for ATM activation 
41. As another example, Heat Shock Protein 90 (HSP90, the prototypical chaperone protein) 
inhibitor treatment inhibits ATM autophosphorylation upon DNA damage 88 and 
destabilizes the MRN complex 89, 90, thereby inhibiting HR. Finally, CDK1 inhibition causes 
the loss of a critical phosphorylation event on BRCA1 required for its HR function 91.  
There are additional modulators of DDR and DNA repair not described here 65. Indeed, the 
number of pharmacologic inhibitors that either directly or indirectly inhibit DSB repair is 
being uncovered at a rapid pace. Careful consideration should be given for combination 
with radiation therapy in clinical trial design. 
4. Closing remarks 
Radiotherapy is the most effective post-surgical treatment modality in the management of 
glioblastoma. Adjuvant radiotherapy alone provides a more than doubling of median 
survival. Incremental gains with additional medical therapy have proven elusive, with most 
agents showing moderate activity in vitro or with encouraging early clinical experience only 
to demonstrate a lack of benefit in larger trials. Attempts at treatment intensification with 
radiotherapy have been similarly disappointing. Molecular understanding of DNA damage 
response and repair, on the other hand, has now afforded novel therapeutic targets. These 
targets are particularly attractive in the context that oncogenes induce increased DNA 
damage accumulation and cause tumors to become hyper-dependent on DNA damage 
response pathways. Encouragingly, several FDA-approved agents modulate critical proteins 
in DNA damage response/repair, including conventional DNA damaging agents, 
proteasome inhibitors, and EGFR inhibitors. Clinical trials involving these and other agents 
modulating DNA damage response should be designed with this consideration.  
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